A proteasome inhibitor effectively prevents mouse heart allograft rejection

Transplantation

Volumn 72, Issue 2, 2001, Pages 196-202

  Luo, Hongyu ^a   Wu, Yulian ^a,c   Qi, Shijie ^a   Wan, Xiaochun ^a   Chen, Huifang ^a   Wu, Jiangping ^a,b  

^a NOTRE DAME HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDE BORONIC ACID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOKINE; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034902852     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200107270-00005     Document Type: Article

References (24)

1. Selective protein degradation: A journey's end within the proteasome
2. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids
3. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
4. Molecular cloning and expression of a gamma-interferon-inducible activator of the multicatalytic protease
5. Role of proteasomes in T cell activation and proliferation
6. Ubiquitination of the G1 cyclin Cln2p by a Cdc34p-dependent pathway
7. p34Cdc28- mediated control of Cln3 cyclin degradation
8. Role of a ubiquitin-conjugating enzyme in degradation
9. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
10. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
11. The ubiquitin-proteasome pathway is required for processing the NF- kappa B1 precursor protein and the activation of NF-kappa B
12. Proteasome regulation of activation-induced T cell death
13. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain
14. Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome
15. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1
16. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
17. Blockade of the interleukin-2 receptor by anti-Tac antibody: Inhibition of human lymphocyte activation
18. New functional activities for the p21 family of CDK inhibitors
19. Role of the proteasome and NF- kappaB in streptococcal cell wall-induced polyarthritis
20. Mechanistic studies on the inactivation of the proteasome by lactacystin: A central role for clasto-lactacystin beta-lactone
21. Rapamycin inhibits proteasome activator expression and proteasome activity
22. Impaired signaling in alloantigen-specific CD8+ T cells tolerized in vivo: Employing a model of Ld-specific TCR transgenic mice transplanted with allogenic hearts under the cover of a short-term Rapamycin treatment